BACKGROUND: (18)Fluoro-2-Deoxy Glucose (18 FDG) positron emission tomography (PET) impacts upon the management of recurrent colorectal cancer (CRC) but is limited by anatomical localisation. The development of integrated positron emission and computerised tomography (PET/CT) yields high anatomical resolution combined with the PET data. We evaluate the added value of PET/CT over PET alone. METHOD: Thirty-one consecutive patients had PET/CT for suspected recurrent CRC. Two blinded observers (A and B) reported images from PET alone and from integrated PET/CT. Lesion detection, lesion localisation, diagnostic certainty and impact on surgical management was assessed for each data set and then compared. The minimum clinical follow up was for 8 months (median 9.6 months) and 7 patients had histological confirmation of diagnosis. RESULTS: Compared to PET alone, PET/CT the percentage of lesions accurately localised increased from 96% to 99% for observer A and 86% to 99% for Observer B. PET/CT increased the number of lesions reported as definitely abnormal or normal from 78% to 95% for Observer A and from 72% to 94% for Observer B. Surgical management was changed in 6 patients (19%). Inter-observer variability was reduced with PET/CT. CONCLUSION: PET/CT improves the accuracy of reporting in recurrent colorectal cancer and influences surgical management in a significant proportion of patients when compared to PET only imaging.
BACKGROUND: (18)Fluoro-2-Deoxy Glucose (18 FDG) positron emission tomography (PET) impacts upon the management of recurrent colorectal cancer (CRC) but is limited by anatomical localisation. The development of integrated positron emission and computerised tomography (PET/CT) yields high anatomical resolution combined with the PET data. We evaluate the added value of PET/CT over PET alone. METHOD: Thirty-one consecutive patients had PET/CT for suspected recurrent CRC. Two blinded observers (A and B) reported images from PET alone and from integrated PET/CT. Lesion detection, lesion localisation, diagnostic certainty and impact on surgical management was assessed for each data set and then compared. The minimum clinical follow up was for 8 months (median 9.6 months) and 7 patients had histological confirmation of diagnosis. RESULTS: Compared to PET alone, PET/CT the percentage of lesions accurately localised increased from 96% to 99% for observer A and 86% to 99% for Observer B. PET/CT increased the number of lesions reported as definitely abnormal or normal from 78% to 95% for Observer A and from 72% to 94% for Observer B. Surgical management was changed in 6 patients (19%). Inter-observer variability was reduced with PET/CT. CONCLUSION: PET/CT improves the accuracy of reporting in recurrent colorectal cancer and influences surgical management in a significant proportion of patients when compared to PET only imaging.
Authors: M H Whiteford; H M Whiteford; L F Yee; O A Ogunbiyi; F Dehdashti; B A Siegel; E H Birnbaum; J W Fleshman; I J Kodner; T E Read Journal: Dis Colon Rectum Date: 2000-06 Impact factor: 4.585
Authors: Y Fong; P F Saldinger; T Akhurst; H Macapinlac; H Yeung; R D Finn; A Cohen; N Kemeny; L H Blumgart; S M Larson Journal: Am J Surg Date: 1999-10 Impact factor: 2.565
Authors: T J M Ruers; B S Langenhoff; N Neeleman; G J Jager; S Strijk; Th Wobbes; F H M Corstens; W J G Oyen Journal: J Clin Oncol Date: 2002-01-15 Impact factor: 44.544
Authors: Victor Kalff; Rodney J Hicks; Robert E Ware; Annette Hogg; David Binns; Allan F McKenzie Journal: J Nucl Med Date: 2002-04 Impact factor: 10.057
Authors: Darius C Desai; Emanuel E Zervos; Mark W Arnold; William E Burak; Joseph Mantil; Edward W Martin Journal: Ann Surg Oncol Date: 2003 Jan-Feb Impact factor: 5.344
Authors: M Simó; F Lomeña; J Setoain; G Pérez; P Castellucci; J M Costansa; J Setoain-Quinquer; F Doménech-Torné; I Carrió Journal: Nucl Med Commun Date: 2002-10 Impact factor: 1.690